Yunzi Chen1, Jie Du, Zhongyi Zhang, Tianjing Liu, Yongyan Shi, Xin Ge, Yan Chun Li. 1. *Laboratory of Metabolic Disease Research and Drug Development, China Medical University, Shenyang, Liaoning, China; †Division of Biological Sciences, Department of Medicine, The University of Chicago, Chicago, Illinois; and ‡Department of Pediatrics, Shengjing Hospital, China Medical University, Shenyang, Liaoning, China. Dr Chen is now with the Department of Microbiology and Immunology, Nanjing Medical University, Nanjing, China.
Abstract
BACKGROUND: We recently reported that the gut epithelial vitamin D receptor (VDR) signaling inhibits colitis through inhibition of intestinal epithelial cell apoptosis, and the level of colonic epithelial VDR is markedly reduced in patients with inflammatory bowel diseases (IBD). VDR downregulation promotes colitis, but the mechanism underlying VDR downregulation in IBD is unknown. METHODS: VDR expression was analyzed in colon cancer cells under proinflammatory cytokine treatment. VDR as a target of miR-346 was confirmed using colon cancer cell culture. The relationship among inflammation, miR-346, and VDR was assessed in human IBD biopsies and experimental colitis models. RESULTS: We showed that tumor necrosis factor α (TNF-α) suppresses VDR expression while simultaneously upregulating miR-346 in human colon cancer cells. Further studies demonstrated that miR-346 inhibits VDR by a specific target sequence in the 3' untranslated region of the human VDR transcript, and blockade of miR-346 with a hairpin inhibitor abrogates the ability of TNF-α to inhibit VDR, confirming that TNF-α downregulates VDR by inducing miR-346. Consistently, in human IBD biopsies, the reduction of epithelial VDR is associated with increased immune cell infiltration and elevation of TNF-α and miR-346. In an experimental model of colitis, mucosal VDR expression is reduced over time with the progression of colitis, inversely correlated with the induction of TNF-α and miR-346 in the mucosa. CONCLUSIONS: These data suggest that during mucosal inflammation TNF-α induces miR-346, which downregulates epithelial VDR. Mucosal VDR reduction in turn compromises the integrity of the mucosal epithelial barrier, further driving mucosal inflammation and colitis development.
BACKGROUND: We recently reported that the gut epithelial vitamin D receptor (VDR) signaling inhibits colitis through inhibition of intestinal epithelial cell apoptosis, and the level of colonic epithelial VDR is markedly reduced in patients with inflammatory bowel diseases (IBD). VDR downregulation promotes colitis, but the mechanism underlying VDR downregulation in IBD is unknown. METHODS:VDR expression was analyzed in colon cancer cells under proinflammatory cytokine treatment. VDR as a target of miR-346 was confirmed using colon cancer cell culture. The relationship among inflammation, miR-346, and VDR was assessed in human IBD biopsies and experimental colitis models. RESULTS: We showed that tumor necrosis factor α (TNF-α) suppresses VDR expression while simultaneously upregulating miR-346 in humancolon cancer cells. Further studies demonstrated that miR-346 inhibits VDR by a specific target sequence in the 3' untranslated region of the humanVDR transcript, and blockade of miR-346 with a hairpin inhibitor abrogates the ability of TNF-α to inhibit VDR, confirming that TNF-α downregulates VDR by inducing miR-346. Consistently, in human IBD biopsies, the reduction of epithelial VDR is associated with increased immune cell infiltration and elevation of TNF-α and miR-346. In an experimental model of colitis, mucosal VDR expression is reduced over time with the progression of colitis, inversely correlated with the induction of TNF-α and miR-346 in the mucosa. CONCLUSIONS: These data suggest that during mucosal inflammationTNF-α induces miR-346, which downregulates epithelial VDR. Mucosal VDR reduction in turn compromises the integrity of the mucosal epithelial barrier, further driving mucosal inflammation and colitis development.
Authors: Yunzi Chen; Weicheng Liu; Tao Sun; Yong Huang; Youli Wang; Dilip K Deb; Dosuk Yoon; Juan Kong; Ravi Thadhani; Yan Chun Li Journal: J Immunol Date: 2013-02-22 Impact factor: 5.422
Authors: D J Berg; N Davidson; R Kühn; W Müller; S Menon; G Holland; L Thompson-Snipes; M W Leach; D Rennick Journal: J Clin Invest Date: 1996-08-15 Impact factor: 14.808
Authors: Ashwin N Ananthakrishnan; Hamed Khalili; Leslie M Higuchi; Ying Bao; Joshua R Korzenik; Edward L Giovannucci; James M Richter; Charles S Fuchs; Andrew T Chan Journal: Gastroenterology Date: 2011-12-09 Impact factor: 22.682
Authors: Mark R Haussler; G Kerr Whitfield; Ichiro Kaneko; Carol A Haussler; David Hsieh; Jui-Cheng Hsieh; Peter W Jurutka Journal: Calcif Tissue Int Date: 2012-07-11 Impact factor: 4.333
Authors: Weicheng Liu; Yunzi Chen; Maya Aharoni Golan; Maria L Annunziata; Jie Du; Urszula Dougherty; Juan Kong; Mark Musch; Yong Huang; Joel Pekow; Changqing Zheng; Marc Bissonnette; Stephen B Hanauer; Yan Chun Li Journal: J Clin Invest Date: 2013-08-15 Impact factor: 14.808
Authors: Lei He; Tianjing Liu; Yongyan Shi; Feng Tian; Huiyuan Hu; Dilip K Deb; Yinyin Chen; Marc Bissonnette; Yan Chun Li Journal: Endocrinology Date: 2018-02-01 Impact factor: 4.736